The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma

Cell Cycle

Volumn 11, Issue 3, 2012, Pages 569-581

  Liguori, Lucia ^a,b   Andolfo, Immacolata ^a,b   De Antonellis, Pasqualino ^a,b   Aglio, Veruska ^a,b   Di Dato, Valeria ^a,b   Marino, Natascia ^a,b   Orlotti, Nicola Ivan ^a,b   De Martino, Daniela ^a,b   Capasso, Mario ^a,b   Petrosino, Giuseppe ^a   Schramm, Alexander ^c   Navas, Luigi ^b   Tonini, Gian Paolo ^d   Eggert, Angelika ^c   Iolascon, Achille ^a,b   Zollo, Massimo ^a,b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Gene expression; Mpped2; Neuroblastoma; Retinoic acid; Xenograft

Indexed keywords

CASPASE 3; METALLOPROTEIN; PHOSPHODIESTERASE; RETINOIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DNA MICROARRAY; ENZYME ACTIVATION; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; METALLOPHOSPHODIESTERASE 2 GENE; MICROARRAY ANALYSIS; MOUSE; NEOPLASM; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; NULL ALLELE; SAMPLE SIZE; SURVIVAL RATE; TUMOR CELL LINE; TUMOR GROWTH; XENOGRAFT;

EID: 84857207605     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.3.19063     Document Type: Article

References (47)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369:2106-20; PMID:17586306; http://dx.doi.org/10.1016/S0140-6736(07)60983-0.
2. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999; 17:2264-79; PMID:10561284.
3. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol 2001; 54:897- 910; PMID:11729208; http://dx.doi.org/10.1136/ jcp.54.12.897.
4. D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 297:1046-9; PMID:4102970; http:// dx.doi.org/10.1016/S0140-6736(71)91606-0.
5. Vermeulen J, De Preter K, Mestdagh P, Laureys G, Speleman F, Vandesompele J. Predicting outcomes for children with neuroblastoma. Discov Med 2010; 10:29-36; PMID:20670596.
6. Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 1982; 68:589-96; PMID:7040765.
7. Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Retinoid therapy of high-risk neuroblastoma. Cancer Lett 2003; 197:185-92; PMID:12880980; http:// dx.doi.org/10.1016/S0304-3835(03)00108-3.
8. Matthay KK, Seeger RC, Reynolds CP, Stram DO, O'Leary M, Harris RE, et al. Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma. Prog Clin Biol Res 1994; 385:301-7; PMID:7972225.
9. Rana B, Veal GJ, Pearson AD, Redfern CP. Retinoid X receptors and retinoid response in neuroblastoma cells. J Cell Biochem 2002; 86:67-78; PMID:12112017; http://dx.doi.org/10.1002/jcb.10192.
10. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. N Engl J Med 1999; 341:1165-73; PMID:10519894; http://dx.doi.org/10.1056/NEJM199910143411601.
11. Seeger RC, Siegel SE, Sidell N. Neuroblastoma: clinical perspectives, monoclonal antibodies and retinoic acid. Ann Intern Med 1982; 97:873-84; PMID:6756240.
12. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, et al. Response of neuroblastoma to retinoic acid in vitro and in vivo. Prog Clin Biol Res 1991; 366:203-11; PMID:2068138.
13. Sucov HM, Evans RM. Retinoic acid and retinoic acid receptors in development. Mol Neurobiol 1995; 10:169-84; PMID:7576306; http://dx.doi.org/10. 1007/BF02740674.
14. Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7:337-50; PMID:15837623; http://dx.doi.org/10.1016/j.ccr.2005.03.019.
15. Hiyama E, Hiyama K, Yamaoka H, Sueda T, Reynolds CP, Yokoyama T. Expression profiling of favorable and unfavorable neuroblastomas. Pediatr Surg Int 2004; 20:33-8; PMID:14691637; http://dx.doi.org/10.1007/ s00383-003-1077-3.
16. Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H, et al. Expression profiling and characterization of 4,200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003; 22:5525-36; PMID:12934113; http://dx.doi.org/10.1038/sj.onc.1206853.
17. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10:4-12; PMID:14734444; http:// dx.doi.org/10.1158/1078- 0432.CCR-1051-2.
18. Wei JS, Greer BT, Westermann F, Steinberg SM, Son CG, Chen QR, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004; 64:6883-91; PMID:15466177; http://dx.doi. org/10.1158/0008-5472.CAN-04-0695.
19. Takita J, Ishii M, Tsutsumi S, Tanaka Y, Kato K, Toyoda Y, et al. Gene expression profiling and identification of novel prognostic marker genes in neuroblastoma. Genes Chromosomes Cancer 2004; 40:120-32; PMID:15101045; http://dx.doi.org/10.1002/ gcc.20021.
20. Bonetta L, Kuehn SE, Huang A, Law DJ, Kalikin LM, Koi M, et al. Wilms tumor locus on 11p13 defined by multiple CpG island-associated transcripts. Science 1990; 250:994-7; PMID:2173146; http://dx.doi. org/10.1126/science. 2173146.
21. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343:774-8; PMID:2154702; http:// dx.doi.org/10.1038/ 343774a0.
22. Schwartz F, Neve R, Eisenman R, Gessler M, Bruns G. A WAGR region gene between PAX-6 and FSHB expressed in fetal brain. Hum Genet 1994; 94:658- 64; PMID:7527372; http://dx.doi.org/10.1007/ BF00206960.
23. Schwartz F, Ota T. The 239AB gene on chromosome 22: a novel member of an ancient gene family. Gene 1997; 194:57-62; PMID:9266672; http://dx.doi. org/10.1016/S0378-1119(97)00149-2.
24. Richter W. 3',5' Cyclic nucleotide phosphodiesterases class III: members, structure and catalytic mechanism. Proteins 2002; 46:278-86; PMID:11835503; http:// dx.doi.org/10.1002/prot.10049.
25. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 2007; 76:481-511; PMID:17376027; http://dx.doi. org/10.1146/annurev. biochem.76.060305.150444.
26. Mehats C, Andersen CB, Filopanti M, Jin SL, Conti M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 2002; 13:29-35; PMID:11750860; http://dx.doi. org/10.1016/S1043-2760(01) 00523-9.
27. Imamura R, Yamanaka K, Ogura T, Hiraga S, Fujita N, Ishihama A, et al. Identification of the cpdA gene encoding cyclic 3′,5′-adenosine monophosphate phosphodiesterase in Escherichia coli. J Biol Chem 1996; 271:25423-9; PMID:8810311; http://dx.doi. org/10.1074/jbc.271.41.25423.
28. Macfadyen LP, Ma C, Redfield RJ. A 3′,5′-cyclic AMP (cAMP) phosphodiesterase modulates cAMP levels and optimizes competence in Haemophilus influenzae Rd. J Bacteriol 1998; 180:4401-5; PMID:9721275.
29. Shenoy AR, Sreenath N, Podobnik M, Kovacevic M, Visweswariah SS. The Rv0805 gene from Mycobacterium tuberculosis encodes a 3′,5′-cyclic nucleotide phosphodiesterase: biochemical and mutational analysis. Biochemistry 2005; 44:15695-704; PMID:16313172; http://dx.doi.org/10.1021/bi0512391.
30. Tyagi R, Shenoy AR, Visweswariah SS. Characterization of an evolutionarily conserved metallophosphoesterase that is expressed in the fetal brain and associated with the WAGR syndrome. J Biol Chem 2009; 284:5217- 28; PMID:19004815; http://dx.doi.org/10.1074/jbc. M805996200.
31. Page CP, Spina D. Phosphodiesterase inhibitors in the treatment of inflammatory diseases. Handb Exp Pharmacol 2011; 204:391-414; PMID:21695650; http://dx.doi.org/10.1007/978-3-642-17969-3-17.
32. Bjørgo E, Moltu K, Taskén K. Phosphodiesterases as targets for modulating T-cell responses. Handb Exp Pharmacol 2011; 204:345-63; PMID:21695648; http://dx.doi.org/10.1007/978-3-642-17969-3-15.
33. Hertz AL, Beavo JA. Cyclic nucleotides and phosphodiesterases in monocytic differentiation. Handb Exp Pharmacol 2011; 204:365-90; PMID:21695649; http://dx.doi.org/10.1007/978-3-642-17969-3-16.
34. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA 2010; 107:18202-7; PMID:20884855; http:// dx.doi.org/10.1073/pnas.1006965107.
35. Horvath A, Korde L, Greene MH, Libe R, Osorio P, Faucz FR, et al. Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors. Cancer Res 2009; 69:5301- 6; PMID:19549888; http://dx.doi.org/10.1158/0008-5472.CAN-09-0884.
36. Levy I, Horvath A, Azevedo M, de Alexandre RB, Stratakis CA. Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment. Curr Opin Pharmacol 2011; 11:689-97; PMID:22047791; http://dx.doi. org/10.1016/j.coph.2011.10.003.
37. Marino N, Zollo M. Understanding h-prune biology in the fight against cancer. Clin Exp Metastasis 2007; 24:637-45; PMID:17952613; http://dx.doi. org/10.1007/s10585-007-9109-3.
38. De Preter K, Vandesompele J, Menten B, Carr P, Fiegler H, Edsjö A, et al. Positional and functional mapping of a neuroblastoma differentiation gene on chromosome 11. BMC Genomics 2005; 6:97; PMID:16000168; http://dx.doi.org/10. 1186/1471-2164-6-97.
39. 2+-dependent phosphodiesterase encoded by the yfcE gene. Protein Sci 2007; 16:1338-48; PMID:17586769; http://dx.doi.org/10.1110/ps.072764907.
40. Vogel A, Schilling O, Niecke M, Bettmer J, Meyer- Klaucke W. ElaC encodes a novel binuclear zinc phosphodiesterase. J Biol Chem 2002; 277:29078- 85; PMID:12029081; http://dx.doi.org/10.1074/jbc.M112047200.
41. Dermol U, Janardan V, Tyagi R, Visweswariah SS, Podobnik M. Unique utilization of a phosphoprotein phosphatase fold by a mammalian phosphodiesterase associated with WAGR syndrome. J Mol Biol 2011; 412:481-94; PMID:21824479; http://dx.doi.org/10.1016/j.jmb.2011.07.060.
42. Friedman HS, Burger PC, Bigner SH, Trojanowski JQ, Wikstrand CJ, Halperin EC, et al. Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol 1985; 44:592-605; PMID:4056828; http://dx.doi.org/10.1097/00005072-198511000-00005.
43. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR. Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol Res 1995; 7:493-503; PMID:8866661.
44. Barnes EN, Biedler JL, Spengler BA, Lyser KM. The fine structure of continuous human neuroblastoma lines SK-N-SH, SK-N-BE(2) and SK-N-MC. In Vitro 1981; 17:619-31; PMID:7327593; http://dx.doi. org/10.1007/BF02618461.
45. Kanda N, Schreck R, Alt F, Bruns G, Baltimore D, Latt S. Isolation of amplified DNA sequences from IMR-32 human neuroblastoma cells: facilitation by fluorescence-activated flow sorting of metaphase chromosomes. Proc Natl Acad Sci USA 1983; 80:4069-73; PMID:6575396; http://dx.doi.org/10.1073/ pnas.80.13.4069.
46. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983; 71:741- 7; PMID:6137586.
47. Schwartz F, Eisenman R, Knoll J, Gessler M, Bruns G. cDNA sequence, genomic organization and evolutionary conservation of a novel gene from the WAGR region. Genomics 1995; 29:526-32; PMID:8666403; http://dx.doi.org/10.1006/geno. 1995.9973.